BOEUF
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.81 | $324M | $74M |
| 2025 Q4 | 0.67 | $312M | $53M |
| 2025 Q3 | 0.52 | $292M | $70M |
| 2025 Q2 | 0.81 | $284M | $48M |
| 2025 Q1 | 0.16 | $284M | $46M |
| 2024 Q4 | 0.82 | $257M | $72M |
| 2024 Q3 | 0.46 | $238M | $42M |
| 2024 Q2 | 0.42 | $220M | -$69M |